Correlation Between Adiponectin, Tumor Necrosis Factor-alpha, Insulin Resistance and Atherogenic Dyslipidemia in Non Diabetic Central Obese Males

Candra Ninghayu, Andi Wijaya, Suryani As'ad


BACKGROUND: Obesity raises the risk for atherosclerotic cardiovascular disease (ASCVD) through many risk factors including atherogenic dyslipidemia. Atherogenic dyslipidemia is characterized by high levels of triglyceride, increased small dense low density lipoprotein particles, and reduced levels of high density lipoprotein cholesterol. The exact mechanisms of central obesity and this atherogenic lipoprotein phenotype (ALP) is not clearly understood. Central obesity is characterized by a state of systemic low grade inflammation and insulin resistance. Adipose tissue has recently been shown to secrete a variety of bioactive peptides, called adipocytokines, that can potentially affect glucose and lipid metabolism. The aim of this study was to observe the role of adiponectin, tumor necrosis factor-α (TNF- α) and insulin resistance in atherogenic dyslipidemia in nondiabetic central obese males.

METHODS: This was a cross-sectional study on 75 non-diabetic central obese male subjects (waist circumferences > 90 cm). Adiponectin and TNF-α testing were performed by ELISA; insulin resistance was assessed by the Homeostasis Model Assessment (HOMA) index, triglyceride was assessed by GPO-PAP, HDL cholesterol and small dense LDL were measured by homogenous method. Statistical analysis was done by SPSS for Windows v. 11.5 with a significance level at p < 0.05. The Pearson and Spearman’s Rho correlation coefficient was used to assess the correlation between various anthropometric and biochemical parameters.

RESULTS: There were 75 patients aged 38.0±6.3 years, Adiponectin concentration was 3.55±1.38 μg/ml, HOMA index was 2.28±1.63, TNF-α was 12.42±11.25 pg/ml, triglyceride was 185.17±109.00, HDL-cholesterol was 44.15±9.23 mg/dL, small dense LDL 23.22±12.26 mg/dL. This study revealed that there were correlations between adiponectin and triglyceride (r=-0.236, p=0.042), adiponectin and HDL cholesterol (r=0.300, p=0.009), adiponectin and atherogenic dyslipidemia (r=-0.256, p=0.027), whereas there was no correlation between insulin resistance and TNF-α with the atherogenic dyslipidemia.

CONCLUSION: Adiponectin might contribute to atherogenic dyslipidemia in central obese non-diabetic males. Advancing our understanding of the function and measurement of adiponectin serum concentration will be useful in clinical diagnosis of obesity related atherogenic dyslipidemia.

KEYWORDS: obesity, waist circumference, adiponectin, insulin resistance, TNF-α, atherogenic dyslipidemia

Full Text:



Krauss RM, Blanche PJ, Rawlings RS, Fernstrom HS, Williams PT. Separate effects of reduced carbohydrate intake and weight loss on atherogenic dyslipidemia. J Clin Nutr. 2006; 83 : 1025-31, PMID.

Bamba V, Rader DJ. Obesity and atherogenic dyslipidemia. Gastroenterology. 2007; 132 : 2181-90, CrossRef.

Grundy SM, Abate N. Obesity. In: Secondary Heart Disease: Systemic Disease and The Heart. 2nd ed. [n.p]: [n.p]; 2002. p.1463-68.

Chan DC, Watts GF, Ng TWK, Uchida Y, Sakai N, Yamashita S, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem. 2005; 51: 578-85, CrossRef.

Cawthorn WP, Sethi JK. TNF-α and adipocyte Biology. FEBS Lett. 2008; 582: 117-31, CrossRef.

Van der Vleuten GM, van Tits LJH, den Heijer M, Lemmers H, Stalenhoef AFH, de Graaf J. Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile. J Lipid Res. 2005; 46: 2398-404, CrossRef.

Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab. 2002; 87: 2764-9, CrossRef.

Ebinuma H, Miyazaki O, Yago H, Hara K, Yamauchi T, Kadowaki T. A novel ELISA system for selective measurement of human adiponectin multimers by using proteases. Clin Chem Acta. 2006; 372: 47-53, CrossRef.

Chan DC, Barrett PHR, Ooi EMM, Ji J, Chan DT, Watts GF. Very low density lipoprotein metabolism and plasma adiponectin as predictors of high-density lipoprotein apolipoprotein A-I kinetics in obese and nonobese men. J Clin Endocrinol Metab. 2009; 94: 989-97, CrossRef.

Von Eynatten M, Hamann A, Twardella D, Nawroth PP, Brenner H, Rothenbacher D. Relationship of adiponectin with markers of systemic inflammation, atherogenic dyslipidemia, and heart failure in patients with coronary heart disease. Clin Chem. 2006; 52: 853-9, CrossRef.

Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003; 46: 459-69, PMID.

Sethi JK, Puig AJV. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007; 48: 1253-62, CrossRef.


Indexed by:






©2018, The Prodia Education and Research Institute. All rights reserved.